Kalytera Announces Engagement of Echelon Wealth Partners to Assist with Review of Potential Out-License Opportunities for Commercial Rights to GVHD Products
May 21, 2019 09:00 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, May 21, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") has engaged Echelon Wealth Partners...
Kalytera Reports Data for First Cohort in Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD
March 22, 2019 07:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, March 22, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced positive data...
Kalytera Announces Initiation of Study KAL-07 – Food Effect Study
March 06, 2019 07:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, March 06, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has...
Kalytera Reports Additional Positive Data for CBD in Prevention of Acute GVHD
February 05, 2019 07:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced additional...
Kalytera Announces Initiation of Research Coverage by Echelon Wealth Partners
January 15, 2019 07:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") announced that Echelon Wealth...
Kalytera Provides Update on Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD
December 20, 2018 12:10 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced positive interim...
Kalytera Announces Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain
September 27, 2018 07:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced a major step...
Kalytera Therapeutics Provides Update for Lead Program in Prevention and Treatment of GVHD
September 20, 2018 07:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today provided an update on its...
Kalytera Reports Second Quarter 2018 Financial Results
August 30, 2018 07:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results...
Kalytera Completes Pre-IND Meeting with FDA
August 02, 2018 08:00 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, Calif. and TEL AVIV, Israel, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it...